Comparison of vinblastine and interferon alpha with 5-flourouracil treatment in metastatic renal cell carcinoma: A preliminary report Metastatik renal hucreli kanserde vinblastin ile interferon alfa ve 5- florourasil tedavisinin karsilastirilmasi: On rapor


Erciyes Tip Dergisi, vol.21, no.2, pp.111-116, 1999 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 2
  • Publication Date: 1999
  • Journal Name: Erciyes Tip Dergisi
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.111-116
  • Erciyes University Affiliated: Yes


Purpose: Fourteen patients with metastatic renal cell cancer were evaluated prospectively in the Urology Clinic of the Faculty of Medicine at Erciyes University between 1991 and 1997. Materials and methods: The patients were randomized. Vinblastine was given to seven patients and combined therapy (Interferon alpha 2a and 5-flourouracil) was given to the other seven patients. Results: The duration of therapy for the vinblastine group was a median of 28 (min-max; 6-36) weeks and follow-up time was a median of 28 (min-max; 6-102) weeks. Six patients died due to the progression of the disease in a median of 28 (min-max; 6-31) weeks. One other patient in this group died after two years. Six patients in the combined group died because of the progression of the disease in the median of 23 (min-max; 4-50) weeks. One patient, who showed lung metastases after the treatment, has been followed-up for 108 weeks. The one year survival rate was found to be 14 % in both groups. Leucopenia developed in four patients in the vinblastine group. In one patient, chemotherapy was discontinued in the 36th month of therapy since severe leucopenia developed. In the combination therapy group, one patient exhibited a high fever (39C°) due to interferon therapy. Conclusion: Although the number of patients in this study is not adequate, the current results show that systemic chemotherapy and immunotherapy regimens are not effective for the patients with renal cell carcinoma and more effective agents are needed.